Discovery of highly potent pancoronavirus fusion inhibitors that also effectively inhibit COVID-19 variants from the UK (Alpha), South Africa (Beta), and India (Delta)

Article Information

doi

History

^aLaboratory of Molecular Modeling & Drug Design, Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York, USA
^bDepartment of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, Texas, USA
^cDepartment of Chemistry & Physics, Augusta University, Augusta, Georgia 30912, USA
^dEDASA Scientific, Scientific Campus, Moscow State University, Leninskie Gory Bld. 75, 77-101b, Moscow 119992, Russia
^eCenter of Biodefense and Emerging Disease, The University of Texas Medical Branch, Galveston, Texas, USA
^fLindsley F. Kimball Research Institute, New York Blood Center, New York, New York, USA

↵*Corresponding authors Francesca Curreli- Laboratory of Molecular Modeling & Drug Design, Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York, USA; Phone: +1-212-570- 3102; Email: fcurreli{at}nybc.org, Asim K Debnath- Laboratory of Molecular Modeling & Drug Design, Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York, USA; Phone: +1-212-570-3373; Email: adebnath{at}nybc.org